Tianjin Tianyao Pharmaceuticals Co Ltd (600488) - Total Liabilities
Based on the latest financial reports, Tianjin Tianyao Pharmaceuticals Co Ltd (600488) has total liabilities worth CN¥1.85 Billion CNY (≈ $270.54 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Tianjin Tianyao Pharmaceuticals Co Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Tianjin Tianyao Pharmaceuticals Co Ltd - Total Liabilities Trend (1998–2024)
This chart illustrates how Tianjin Tianyao Pharmaceuticals Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 600488 total assets.
Tianjin Tianyao Pharmaceuticals Co Ltd Competitors by Total Liabilities
The table below lists competitors of Tianjin Tianyao Pharmaceuticals Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Amphastar P
NASDAQ:AMPH
|
USA | $975.61 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs2.75 Billion |
|
Amerant Bancorp Inc.
NYSE:AMTB
|
USA | $8.84 Billion |
|
GuoChuang Software Co Ltd
SHE:300520
|
China | CN¥1.89 Billion |
|
Montnets Cloud Technology Group Co Ltd
SHE:002123
|
China | CN¥1.58 Billion |
|
Crystal Growth & Energy Equipment Co. Ltd. A
SHG:688478
|
China | CN¥199.93 Million |
|
Hainan Development Holdings Nanhai Co Ltd
SHE:002163
|
China | CN¥4.96 Billion |
|
Plymouth Industrial REIT Inc
NYSE:PLYM
|
USA | $1.02 Billion |
Liability Composition Analysis (1998–2024)
This chart breaks down Tianjin Tianyao Pharmaceuticals Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 600488 net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tianjin Tianyao Pharmaceuticals Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tianjin Tianyao Pharmaceuticals Co Ltd (1998–2024)
The table below shows the annual total liabilities of Tianjin Tianyao Pharmaceuticals Co Ltd from 1998 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.81 Billion ≈ $265.21 Million |
-24.14% |
| 2023-12-31 | CN¥2.39 Billion ≈ $349.61 Million |
-17.53% |
| 2022-12-31 | CN¥2.90 Billion ≈ $423.90 Million |
+14.58% |
| 2021-12-31 | CN¥2.53 Billion ≈ $369.95 Million |
+5.19% |
| 2020-12-31 | CN¥2.40 Billion ≈ $351.70 Million |
+41.78% |
| 2019-12-31 | CN¥1.70 Billion ≈ $248.07 Million |
+11.65% |
| 2018-12-31 | CN¥1.52 Billion ≈ $222.18 Million |
+31.59% |
| 2017-12-31 | CN¥1.15 Billion ≈ $168.83 Million |
+125.69% |
| 2016-12-31 | CN¥511.21 Million ≈ $74.81 Million |
-12.53% |
| 2015-12-31 | CN¥584.42 Million ≈ $85.52 Million |
+16.57% |
| 2014-12-31 | CN¥501.34 Million ≈ $73.36 Million |
-36.19% |
| 2013-12-31 | CN¥785.64 Million ≈ $114.96 Million |
+8.50% |
| 2012-12-31 | CN¥724.13 Million ≈ $105.96 Million |
-0.79% |
| 2011-12-31 | CN¥729.86 Million ≈ $106.80 Million |
-43.34% |
| 2010-12-31 | CN¥1.29 Billion ≈ $188.50 Million |
+20.67% |
| 2009-12-31 | CN¥1.07 Billion ≈ $156.21 Million |
-0.04% |
| 2008-12-31 | CN¥1.07 Billion ≈ $156.27 Million |
+24.96% |
| 2007-12-31 | CN¥854.65 Million ≈ $125.06 Million |
-36.59% |
| 2006-12-31 | CN¥1.35 Billion ≈ $197.24 Million |
+44.40% |
| 2005-12-31 | CN¥933.43 Million ≈ $136.59 Million |
+72.50% |
| 2004-12-31 | CN¥541.10 Million ≈ $79.18 Million |
-19.15% |
| 2003-12-31 | CN¥669.25 Million ≈ $97.93 Million |
+5.48% |
| 2002-12-31 | CN¥634.50 Million ≈ $92.85 Million |
+51.29% |
| 2001-12-31 | CN¥419.39 Million ≈ $61.37 Million |
+44.11% |
| 2000-12-31 | CN¥291.03 Million ≈ $42.59 Million |
+9.99% |
| 1999-12-31 | CN¥264.61 Million ≈ $38.72 Million |
+27.88% |
| 1998-12-31 | CN¥206.93 Million ≈ $30.28 Million |
-- |
About Tianjin Tianyao Pharmaceuticals Co Ltd
Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research and development, production, and sales of corticosteroids, amino acid active pharmaceutical ingredients (APIs), and preparations in China. The company's primary products comprising corticosteroid raw materials, such as dexamethasone, prednisone, methylprednisolone, and betamethasone product series. The company provides amino acid r… Read more